Comparative Plasma Exposure of Albendazole after Administration of Rapidly Disintegrating Tablets in Dogs

Table 4

Comparative plasma disposition kinetic variables for albendazole sulfoxide (ABZSO) and albendazole sulphone (ABZSO₂) after the oral administration of three different formulations.

Pk parameters	Group I (ABZ control) conventional tablets		Group II Rapidly disintegrating tablets
	ABZSO	ABZSO2	ABZSO	ABZSO2
𝑇1/2abs. (h)	2.14±1.28	2.46±1.81	2.38±0.42	4.93±1.81
𝑇max (h)	6.00±2.31	7.13±4.80	7.20±1.79	12±0.00
𝑇1/2elim. (h)	4.67±1.68	32.13±39.63	4.73±1.19	10.86±7.47
𝐶max (µg/mL)	5.33±2.83	0.67±0.27	8.18^∗±1.47	1.13±0.34
AUC0--∞ (µg·h/mL)	52.20±12.95	33.32±46.20	113.11^∗±22.85	22.32±10.33
AUMC0--∞ (µg·h^2/mL)	718.50±274.17	222.56±149.04	1180.30±306.44	382.18±344.47
MRT (hr)	12.11±3.99	49.76±56.09	10.48±1.78	21.71±10.90
PDP (h)	0.25–24.0	0.25–24.00	0.25–24.0	0.25–24.0

𝑇_1/2abs.: metabolite formation half-life, 𝐶_max: peak concentration, 𝑇_max: time at 𝐶_max, 𝑇_1/2elim.: elimination half life, AUC_0--∞: area under the concentration versus time curve extrapolated to infinity, AUMC_0--∞: area under the moment of the concentration versus time curve extrapolated to infinity, MRT: Mean residence time, and PDP: plasma detection period. (*) values are statistically different to group I at P < 0.05.